Approval · Notice of Compliance 18866 · 2017
JADENU: Notice of Compliance 18866
Issued January 10, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 18866
- Date
- January 10, 2017
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Fullfilment of the post-approval commitments for the notice of compliance with conditions for management of chronic iron overlaod in patients with transfusion-dependent anemias
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| JADENU | Not yet assigned | — |
Medicinal ingredients
- DEFERASIROX 90 MG per TAB
- DEFERASIROX 180 MG per TAB
- DEFERASIROX 360 MG per TAB